Opioid Use Disorder (OUD)

Understanding Opioid Use Disorder

What OUD Is

OUD is a DSM-5 diagnosis applied when opioid use produces a defined pattern of impaired control, social impairment, risky use, and pharmacological dependence over 12 months. It is graded mild, moderate, or severe based on the number of criteria met. The diagnosis replaced the older distinction between opioid abuse and opioid dependence.

What OUD Is Not

OUD is not the same as physical dependence on prescribed opioids. A patient taking opioids as directed for chronic pain may develop tolerance and physical dependence — but if there is no loss of control, no compulsive use, and no use despite consequences, that is not OUD. The distinction matters: confusing the two leads both to undertreatment of pain and to mislabeling of patients.

The Spectrum of Opioids

Opioids include natural derivatives of the opium poppy (morphine, codeine), semi-synthetic compounds (oxycodone, hydrocodone, heroin), and fully synthetic compounds (fentanyl, methadone, tramadol, buprenorphine). They all act at opioid receptors and share the core risks of dependence, tolerance, respiratory depression, and overdose. The synthetic opioid fentanyl is unique because of its very high potency relative to volume — about 50–100 times more potent than morphine.

Who Develops OUD

OUD occurs across every demographic. Pathways vary: medical opioid prescribing has been one route, illicit use another, both can mix, and family or community exposure shapes risk. Stereotypes about who has OUD are inaccurate and harmful — they prevent diagnosis, delay treatment, and produce stigma that itself increases mortality.

DSM-5 Diagnostic Criteria

OUD requires 2 or more of the following 11 criteria within a 12-month period. The tolerance and withdrawal criteria are not counted toward diagnosis when the person is taking opioids solely under appropriate medical supervision.

Impaired Control

1. Opioids taken in larger amounts or over a longer period than intended
2. Persistent desire or unsuccessful efforts to cut down or control use
3. Great deal of time spent obtaining, using, or recovering
4. Craving — strong desire or urge to use

Social Impairment

5. Recurrent use resulting in failure to fulfill major role obligations
6. Continued use despite persistent social or interpersonal problems
7. Important activities given up or reduced

Risky Use

8. Recurrent use in physically hazardous situations
9. Continued use despite persistent physical or psychological problems caused or worsened by opioids

Pharmacological

10. Tolerance — markedly increased amounts needed, or diminished effect with the same amount
11. Withdrawal — characteristic withdrawal syndrome, or opioids taken to relieve or avoid withdrawal

Severity

• Mild: 2–3 criteria
• Moderate: 4–5 criteria
• Severe: 6 or more criteria

Course Specifiers

• In early remission: No criteria (except craving) for 3 to less than 12 months
• In sustained remission: No criteria (except craving) for 12 months or more
• On maintenance therapy: When the person is on a prescribed agonist medication such as methadone or buprenorphine
• In a controlled environment: Access to opioids is restricted

The Fentanyl Era

What Changed

Over the last decade, illicit fentanyl has largely replaced heroin as the dominant opioid in much of the unregulated US drug supply. Counterfeit pills sold as oxycodone, Xanax, or Adderall increasingly contain fentanyl. This change has driven overdose mortality to record highs.

Why Fentanyl Is So Dangerous

• Very high potency in very small volume — minute differences in dose can be fatal
• Inconsistent distribution in illicit batches creates unpredictable doses
• Rapid onset of respiratory depression compared with heroin
• Often present without the user's knowledge
• May require multiple naloxone doses to reverse overdose

Implications for Treatment

The fentanyl era has changed clinical practice. Buprenorphine inductions are more complex because of fentanyl's prolonged tissue presence — precipitated withdrawal is a real risk if buprenorphine is started too soon. Higher buprenorphine doses are more commonly needed. Naloxone availability and overdose education have become essential parts of every treatment encounter.

Xylazine

Xylazine, a veterinary sedative, increasingly contaminates the fentanyl supply. It is not reversed by naloxone, prolongs sedation after fentanyl wears off, and causes severe skin wounds. Treatment systems are still adapting.

Intoxication, Overdose, and Withdrawal

Acute Intoxication

Opioid intoxication produces analgesia, euphoria, sedation, constricted pupils, slowed breathing, and gastrointestinal slowing. Higher doses produce stupor, unconsciousness, and respiratory depression.

Overdose

Opioid overdose typically presents with the classic triad: unconsciousness, slow or absent breathing, and pinpoint pupils. Respiratory failure is the cause of death. Naloxone, given intranasally or by injection, reverses opioid overdose by displacing the opioid at the receptor. Call 911 immediately even when naloxone is given — additional doses may be needed, and re-overdose can occur as naloxone wears off.

Naloxone Access

Naloxone is now available without prescription in most US states, in many countries internationally, and through community distribution programs. Anyone who uses opioids — or has a loved one who does — should carry naloxone. It cannot harm someone who is not overdosing.

Withdrawal Syndrome

Opioid withdrawal is severely uncomfortable but not typically life-threatening in healthy adults. Symptoms include:

• Anxiety, agitation, restlessness, insomnia
• Muscle aches, joint pain
• Sweating, chills, gooseflesh, dilated pupils
• Yawning, runny nose, tearing
• Nausea, vomiting, diarrhea, abdominal cramps
• Severe craving

Timing varies by drug: short-acting opioids (heroin, oxycodone) produce withdrawal beginning 8–24 hours after last use, peaking at 36–72 hours, and largely resolving over 5–10 days. Methadone withdrawal is slower and longer. Post-acute withdrawal symptoms — anxiety, sleep disturbance, low mood — can persist for weeks to months.

Withdrawal in Pregnancy

Untreated opioid withdrawal in pregnancy increases risk of preterm labor and fetal distress. The standard of care is medication-assisted treatment with methadone or buprenorphine throughout pregnancy, not detoxification.

Why Detox Alone Is Dangerous

Detoxification reduces tolerance. People who complete detox without continuing medication face dramatically elevated overdose risk if they relapse — the dose they previously tolerated may now be fatal. Multiple studies have documented increased mortality after abstinence-only treatment that does not include ongoing medication.

Causes and Risk Factors

Genetic

Heritability of OUD is approximately 40–60%. Genetic factors influence opioid receptor function, metabolism, and broader vulnerability to substance use disorders.

Pathways to OUD

• Prescription pathway: Opioids prescribed for acute or chronic pain, dental procedures, or surgery
• Recreational pathway: Non-medical use beginning in adolescence or early adulthood
• Self-medication pathway: Use to manage trauma, depression, anxiety, or chronic pain
• Mixed pathway: Initial prescription use that transitions to illicit use as access changes

Trauma and Adverse Childhood Experiences

Adverse childhood experiences are strongly associated with OUD risk. Trauma history is the rule rather than the exception in clinical populations. Effective treatment usually addresses trauma alongside the substance use.

Co-occurring Psychiatric Conditions

• Depression
• Anxiety disorders
• PTSD
• ADHD
• Borderline personality disorder
• Other substance use disorders, particularly alcohol, benzodiazepine, and stimulant use

Social Determinants

• Poverty and economic instability
• Lack of access to healthcare
• Stigma that delays treatment seeking
• Incarceration history
• Unstable housing
• Limited social support

Harm Reduction

Harm reduction is a set of practical, evidence-based strategies that reduce the negative consequences of drug use without requiring abstinence as a precondition. Harm reduction saves lives, builds trust between people who use drugs and healthcare systems, and creates pathways into treatment that abstinence-only approaches sometimes foreclose.

Core Strategies

• Naloxone distribution: Universal access to overdose reversal medication
• Never use alone: Use with someone present or with telephone overdose detection services
• Fentanyl test strips: Low-cost tools to detect fentanyl in drug samples
• Lower doses after periods of reduced use: Tolerance falls quickly
• Avoid mixing with benzodiazepines and alcohol: Sharply increases overdose risk
• Syringe service programs: Reduce infectious disease transmission
• Drug checking services: Where legally available, allow analysis of substances

Harm Reduction Does Not Reduce Treatment Engagement

Evidence shows that harm reduction services increase, not decrease, eventual engagement in treatment. Building trust and keeping people alive long enough to seek treatment is itself a form of treatment.

Assessment and Diagnosis

Screening

• Single-Question Screen: "How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?"
• TAPS (Tobacco, Alcohol, Prescription medications, illicit Substances): Brief primary care screen
• NIDA Quick Screen: Useful in general medical settings

Clinical Interview

The DSM-5 criteria are applied through a careful interview covering quantity, frequency, pattern, route, source, tolerance, withdrawal, consequences, prior treatment history, and concurrent substance use. Trauma and psychiatric history are essential.

Medical Evaluation

• Urine drug screen (with awareness of fentanyl detection windows)
• Hepatitis B and C screening
• HIV testing
• Tuberculosis screening when indicated
• Pregnancy testing
• Liver and kidney function
• EKG before methadone induction (for QT assessment)

Withdrawal Severity

The Clinical Opiate Withdrawal Scale (COWS) is used to assess severity and guide induction onto buprenorphine.

Differential Diagnosis

• Physical dependence on prescribed opioids without OUD
• Inadequately treated chronic pain
• Other substance use disorders
• Primary mood or anxiety disorder driving substance use

Medications for OUD (MOUD)

Medications for opioid use disorder — sometimes called MOUD, MAT (medication-assisted treatment), or opioid agonist therapy — are the first-line evidence-based treatment. They reduce mortality, reduce illicit use, retain people in treatment, and produce better outcomes than counseling alone in nearly every controlled trial that has tested them. The previously preferred terminology shifted from "MAT" to "MOUD" to emphasize that these medications are the treatment, not an adjunct.

Buprenorphine

A partial opioid agonist with high receptor affinity. Buprenorphine reduces craving, blocks the effect of other opioids, and has a ceiling effect on respiratory depression that makes it substantially safer than full agonists.

• Formulations: sublingual film/tablet (Suboxone, Subutex, Zubsolv), monthly injection (Sublocade), implant
• Available through office-based prescribing
• In the fentanyl era, induction may require low-dose start strategies to avoid precipitated withdrawal

Methadone

A full opioid agonist with a long half-life. Methadone is highly effective for severe OUD, particularly when buprenorphine does not provide adequate suppression of craving.

• Provided through federally regulated Opioid Treatment Programs (in the US)
• Daily dosing, with take-home privileges earned over time
• Strong evidence for mortality reduction and treatment retention
• QT prolongation requires EKG monitoring at higher doses

Naltrexone

An opioid antagonist that blocks opioid effects entirely. Available as monthly extended-release injection (Vivitrol).

• Requires complete opioid abstinence for 7–14 days before induction
• Does not produce dependence or withdrawal on discontinuation
• Strong evidence in motivated patients who can complete the abstinence window
• Risk of overdose from intentional opioid use during treatment and after discontinuation

Duration of MOUD

OUD is a chronic condition. The strongest evidence supports long-term, often indefinite, treatment with buprenorphine or methadone. Tapering off MOUD is associated with substantially increased relapse and overdose risk. The duration of treatment should be a clinical decision, not a moral or insurance-driven one.

Common Misconceptions

• "Using buprenorphine or methadone is just substituting one addiction for another." It is not — these medications stabilize brain physiology and allow functional recovery; their use under medical supervision is treatment, not addiction.
• "Real recovery requires abstinence from all opioids." Outcomes are substantially better for people on long-term MOUD than for abstinence-only approaches.
• "Detox is enough." Detox without medication is associated with increased mortality due to lost tolerance.

Behavioral Treatment and Recovery Support

Behavioral Therapies

• Cognitive Behavioral Therapy: Targets triggers, distorted thinking, and coping skills
• Contingency management: Tangible rewards for verified abstinence; strong evidence in OUD
• Motivational interviewing: Particularly useful in early or ambivalent stages
• Community Reinforcement Approach: Builds non-using reinforcers across life domains
• Trauma-focused therapy: Often essential given the prevalence of trauma in OUD

Mutual-Help Communities

• Narcotics Anonymous (NA): Twelve-step community, widely available
• Methadone Anonymous and SMART Recovery: Welcoming of MOUD
• LifeRing, Recovery Dharma: Secular and Buddhist alternatives

Some twelve-step communities have historically been ambivalent about MOUD. People on medications for OUD should choose recovery communities that affirm their treatment, not undermine it.

Co-occurring Treatment

Concurrent treatment of depression, anxiety, PTSD, ADHD, and chronic pain is essential. Untreated mental illness and pain are major drivers of relapse. Integrated treatment teams produce better outcomes than parallel siloed care.

Recovery Capital

Recovery capital — the internal, social, and environmental resources that support recovery — is one of the strongest predictors of long-term outcome. Stable housing, employment, healthcare, supportive relationships, meaningful activity, and addressing legal entanglements all contribute. Treatment is most effective when paired with concrete support across these domains.

Long-Term Outlook

OUD outcomes have improved dramatically with the spread of MOUD, but mortality remains unacceptably high in untreated populations. The single most important predictor of long-term survival is sustained engagement in treatment with medication.

Supporting a Loved One

What Helps

• Learn about MOUD and advocate for medication-based treatment
• Carry naloxone and know how to use it
• Approach with compassion and accurate information, not shame
• Consider CRAFT — the most evidence-based family approach
• Take care of your own mental health; consider Nar-Anon or therapy

What to Avoid

• Pressuring abstinence-only treatment when MOUD has stronger evidence
• Confrontational interventions, which can backfire
• Threats and ultimatums that you cannot keep
• Treating MOUD as "just trading one drug for another"
• Believing one conversation will produce change

If You Witness an Overdose

• Call 911 immediately — most US states have Good Samaritan laws that protect bystanders
• Administer naloxone if available
• Begin rescue breathing if the person is not breathing
• Put them in the recovery position if breathing
• Stay until help arrives — overdose can recur as naloxone wears off